



IMPACT

UNIVERSITY OF MARYLAND MEDICAL CENTER



Cancer-Free After 25 Years

In celebration of her triumph over cancer, Marlene Greenebaum and her family give back to UMGCC

Marlene Greenebaum gives all new meaning to the term “survivor.” In August 2015, this incredible community leader and philanthropist will commemorate the 25th anniversary of the day she learned she had breast cancer. Every day since has been filled with action and advocacy by Marlene and her family, including her husband and son, Stewart and Michael Greenebaum, as well as her daughter, Amy Burwen, and Amy’s husband, Steve. Together, the family continues to work tirelessly to bring about a better future for cancer patients around the world.

CONTINUED ON PAGE FOUR

IN GRATITUDE

No matter what the initiative, a common thread unites everything we do at UMMC: innovation. Our faculty, staff, partners, and even patients constantly seek creative ways to push the boundaries of medicine, with the ultimate goal of finding new treatments and cures.

In this issue of *IMPACT*, you will read about novel UMMC solutions across the spectrum—from groundbreaking research and care at the Greenebaum Cancer Center, to unique training opportunities in our Orthopaedic Trauma Surgery program, to the formation of a new, independent Board of Directors that will guide our institution through the rapidly changing healthcare marketplace.

Your support continues to play an indispensable role in all of these pursuits, providing us with the resources to turn our creative ideas into tangible solutions. The entire UMMC community owes you a great debt of gratitude for helping us improve the health of patients throughout the region and well beyond.



Janice Eisele
Senior Vice President
UMMC Foundation

University of Maryland Medical Center Appoints New Board of Directors

The University of Maryland Medical Center (UMMC) has a newly-elected Board of Directors, officially creating a new governance structure for the institution. Previously, the University of Maryland Medical System (UMMS) Board of Directors served as the governing body for UMMC.

Louise Michaux Gonzales, Esq., partner and co-founder at the law firm of Hylton & Gonzales, will serve as founding Chair and has been a longstanding advocate and supporter of UMMC through her role as a director of the medical system. “UMMC is a unique and sophisticated organization, and it is a special resource for the entire region. Our care teams integrate research, diagnostics, and therapeutics in ways that have the greatest impact on people’s lives. I am extremely honored to lead this new Board,” says Gonzales.

Board members were selected for their proven business acumen, exemplary leadership abilities, and outstanding commitment to philanthropy and community engagement. “We are privileged to have this diverse and distinguished group of business leaders at the helm,” says Jeffrey A. Rivest, UMMC President and Chief Executive Officer. Adds Janice Eisele, Senior Vice President of the UMMS Foundation, “The members of this board represent some of the most generous leaders in our region. We look forward to working with them to advance philanthropic partnerships and broaden UMMC’s reach in research, teaching, and high quality patient care.”

University of Maryland Medical Center Board of Directors

Louise Michaux Gonzales, Esq., Chair

Stephen A. Burch, JD, Chair, UMMS Board of Directors

Calvin G. Butler Jr., Chief Executive Officer, Baltimore Gas and Electric

Robert A. Chrencik, MBA, CPA, President and Chief Executive Officer, UMMS

Harriet E. Cooperman, Esq., Partner, Saul Ewing LLP

Carol L. Coughlin, CPA, Chief Executive Officer, BottomLine Growth Strategies, Inc.

Mark L. Joseph, Chief Executive Officer, Transdev North America

Jay A. Perman, MD, President, University of Maryland, Baltimore

E. Albert Reece, MD, PhD, MBA, Vice President for Medical Affairs University of Maryland, and the John Z. and Akiko K. Bowers Distinguished

Professor and Dean of the University of Maryland School of Medicine

Tim Regan, President and Chief Executive Officer, The Whiting-Turner Contracting Company

Jeffrey A. Rivest, FACHE, MS, President and Chief Executive Officer, UMMC and UMMC Midtown Campus

Peter Rock, MD, MBA, President of the Medical Staff, University of Maryland Medical Center

Deborah Trautman, PhD, RN, Chief Executive Officer, American Association of Colleges of Nursing

NICU CAMPAIGN UPDATE

New Facility Will Open in July 2015

The Drs. Rouben and Violet Jiji Neonatal Intensive Care Unit (NICU) at the University of Maryland Children’s Hospital will open its doors to patients this July. The new NICU is designed to meet the rapidly growing need for NICU services for premature and critically ill infants, and it also triples the footprint of the current NICU. Jeffrey A. Rivest, President and CEO of the University of Maryland Medical Center (UMMC) notes, “the new setting will seamlessly integrate leading-edge technology and

world-class neonatal care in a family-centered and healing environment. And, it provides new opportunities for innovative research that will benefit our patients for years to come.”

“Thanks to the expertise of everyone involved in this project, and through philanthropic support from our generous benefactors, the renovated and expanded NICU will soon be a reality,” continues Rivest. “We can’t wait to see what a difference this will make for patients and families.”

“The new NICU will transform the way we care for our tiniest and most fragile patients.”

Jeffrey A. Rivest

Grants Advance Innovation and Signature Initiatives

A grant from **CareFirst BlueCross BlueShield** (CareFirst) will fund the acquisition of equipment and software technology in the new Simulation Center, part of the Center for Critical Care and Trauma Education at the R Adams Cowley Shock Trauma Center (STC). Under the leadership of medical director Samuel A. Tisherman, MD, Professor of Surgery at the University of Maryland School of Medicine, the Center further extends STC’s tradition of providing cutting-edge training. In the Simulation Center, high-fidelity training exercises mimic actual hospital cases. Here, faculty physicians, medical and nursing students, and emergency medical personnel and specialists train together in the management of critically ill and injured patients. “CareFirst is proud to offer continued support of the University of Maryland Medical Center’s Shock Trauma training and education capabilities,” says Maria Harris Tildon, Senior Vice President, Public Policy & Community Affairs, CareFirst. “As one of the leading shock trauma centers in the country, UMMC’s commitment to serve our region’s most critically injured individuals with expert medical care is unmatched.”

A simulation exercise mimics a real-life surgical case. To learn more, visit www.ummsfoundation.org/stc



A grant award from **The Hearst Foundations** brings the University of Maryland Children’s Hospital (UMCH) Neonatal Intensive Care Unit (NICU) renovation and expansion project nearer to completion and closer to reaching its \$10 million fundraising campaign goal to support the construction of the new unit. Slated to open to patients this July, the new and expanded Level IV-NICU facility will match the most advanced levels of care for premature and critically ill infants already provided by the experts at UMCH. Furthermore, the new NICU will significantly enhance the capacity to accept patients and provide additional resources and support services. “The Hearst Foundations are pleased to support this very worthy project,” states Mason Granger, Director of Grants for The Hearst Foundations. “We know the new NICU facility will have a major impact on how the NICU teams are able to innovate and provide even more caring, coordinated care.”

For more detail about these innovative projects, visit www.ummsfoundation.org



UMGCC traces its origins to the National Cancer Institute (NCI) intramural program begun in Baltimore in 1965. Since then, our ongoing achievements in cancer care, research, and training have designated us among the nation's top 50 cancer hospitals. Our patients have access to the most advanced cancer therapies combined with compassionate support services that work in tandem to help patients heal faster.

This state-of-the-art care is the direct result of contributions—past, present, and future—from generous benefactors like you. Please accept my deepest thanks for your support.

Kevin J. Cullen, MD

Marlene and Stewart Greenebaum Distinguished Professor of Oncology, University of Maryland School of Medicine

Director, University of Maryland Greenebaum Cancer Center


1982

University of Maryland Cancer Center is formally established.

1993

The Blood and Marrow Transplant program is established.

A volunteer Board of Advisors is created to advance the mission of UMGCC.



1994

The first aromatase inhibitor is released worldwide for treatment of breast cancer; this is a breakthrough made possible through pioneering research by Angela Brodie, PhD.

1996

With a generous gift from the Greenebaum family, the center is renamed the University of Maryland Marlene and Stewart Greenebaum Cancer Center.



Cancer-Free After 25 Years

CONTINUED FROM PAGE ONE

Among the Greenebaums' foremost priorities—supporting cancer initiatives at the University of Maryland Medical Center (UMMC), where Marlene received cutting-edge treatment that helped her triumph over the disease. “I had absolutely wonderful care,” says Marlene, recalling her experience with the outstanding oncologists, nurses, and other support staff involved in her treatment. “Not only are they the best at what they do, but they’re also very compassionate, caring people.”

That experience led Stewart—a top Maryland real-estate developer who was then Chairman of the University of Maryland Medical System (UMMS) Board of Directors and a member of the University of Maryland School of Medicine Board of Advisors—to formulate a special plan for honoring both his beloved wife and the institution that saved her life. “In 1995, on the five-year anniversary of my diagnosis, Stewart said we should commemorate my recovery,” Marlene remembers. “I thought we would just go to dinner; I had no idea he’d reveal a plan to name the cancer center in my honor!”

The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC), named in recognition of the couple’s unprecedented gift to UMMS and the School of Medicine, was announced one year later. The gift enabled UMGCC’s renowned clinical, research, and training programs to reach the next level: UMGCC ultimately became one of only 68 centers in the country to receive the prestigious National Cancer Institute designation, and it is consistently ranked among the nation’s top 50 cancer hospitals by *U.S. News & World Report*.

The transformative gift is just one in a long line of the family’s efforts to improve the lives of cancer patients throughout Baltimore and well beyond. Those efforts include serving on the UMGCC Board of Advisors, where both Greenebaums contributed the wealth of expertise they had gained as board members of various businesses and charities. Stewart became a particularly well-informed advocate for cancer causes: “After I was diagnosed with breast cancer, Stewart researched it from top to bottom,” notes Marlene. “One doctor said he’d never seen a

lay person who was so knowledgeable on the subject.”

The Greenebaums’ son, Michael, also became an avid volunteer—joining the Boards of Advisors of both UMGCC and School of Medicine, and working with his friend and running partner, Jon Sevel, to establish the annual Maryland Half Marathon & 5K benefitting UMGCC. In its seven-year existence, the event has grown to 2,000 participants each year, who have raised nearly \$2 million to date in support of UMGCC programs.

In addition to their volunteerism, the Greenebaums have continued to make major philanthropic investments in UMGCC, including their gift of the Marlene and Stewart Greenebaum Distinguished Professorship in Oncology, held by UMGCC Director Kevin J. Cullen, MD. The couple’s collective contributions have allowed Dr. Cullen and others to make unparalleled progress in the understanding and treatment of cancer among all populations. For instance, Dr. Cullen has demonstrated for the first time that survival disparities in head and neck cancer are largely



Marlene Greenebaum with Katherine Tkaczuk, MD, Professor of Medicine and Director, Breast Evaluation & Treatment Program, UMGCC

explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection. “I’m so proud to support work that is leading to better care for those with cancer—especially the underserved,” says Marlene.

The family’s profound generosity extends to other programs as well, from their support for School of

Medicine scholarships to their latest special gift: the Stewart J. Greenebaum Endowed Professorship in Stroke Neurology, given by Marlene following her husband’s tragic stroke three years ago. “After Stewart’s amazing gesture to name the cancer center in my honor, this professorship was my gift to him.”

Going forward, Marlene intends to continue the work to end cancer that

she and her family began more than two decades ago. “When I was growing up, if people had the ‘Big C,’ they didn’t talk about it,” notes Marlene. “I’m extremely gratified to know that in sharing my story and publicly pledging my support for cancer causes, I have had a role in changing that—and in making life a little brighter for all those with this disease.”



2001

UMGCC establishes the Baltimore City Cancer Program, which offers free breast and cervical health education, screening and diagnostic testing, treatment, and survivorship support to uninsured women in Baltimore City. To date, more than 30,000 city residents have been screened.

2004



Kevin J. Cullen, MD, is appointed director of UMGCC.

2005

Angela Brodie, PhD, is awarded the Kettering Prize from the General Motors Cancer Research Foundation.

UMGCC researchers Angela Brodie, PhD, and Vincent Njar, PhD, publish a paper reporting their discovered compound, now known as galeterone, is their most potent compound for inhibiting prostate cancer. Today, galeterone shows promise in clinical trials as a treatment for the most challenging cases of prostate cancer.

The Roslyn and Leonard Stoler Pavilion opens through a generous gift from the Stoler family.



There Must Be a Better Way

Age-old quandary inspires breakthrough discovery in the treatment of breast cancer

According to the Centers for Disease Control, nearly a quarter of a million women are diagnosed with breast cancer every year in the U.S. One of the most important therapeutic advances to impact the treatment of breast cancer was discovered by Angela H. Brodie, PhD, Professor of Pharmacology at the University of Maryland School of Medicine. It was here in Baltimore that her pioneering research led to the discovery of a class of drugs known as aromatase inhibitors, a landmark advancement that has revolutionized and transformed the treatment of breast cancer in women worldwide.

Early in her career in the lab at Christie Cancer Hospital in Manchester, England, Brodie observed that the treatments for breast cancer were invasive and had terrible side effects. According to Brodie, she, like other notable scientists and innovators, traces her most important discovery back to a single phrase—"there must be a better way." She began to apply her insatiable curiosity and scientific intellect with her passion to devise an improved approach for breast cancer treatment.

This directive would continue to influence Dr. Brodie's work as she moved to the U.S. in the early 1970s to work at the Worcester (Massachusetts) Foundation for Experimental Biology, as the recipient of a prestigious fellowship sponsored by the National Institutes of Health (NIH). It was there that she met her husband, an organic chemist, and they began their collaboration developing inhibitors to block estrogen synthesis. Brodie's hypothesis that these inhibitors could lead to more complete suppression of estrogen garnered important initial research funding by the NIH in 1975.

In 1979, Dr. Brodie relocated her lab to the University of Maryland and continued her research leading to the development of aromatase inhibitors. "As a researcher, it's important to have access to resources of all kinds to be successful—willing and like-minded colleagues, research funding, lab space, and the latest technology and equipment," says Brodie.

Leveraging these resources, Dr. Brodie validated her hypothesis. As a class of drugs, aromatase inhibitors help prevent the recurrence of breast cancer in post-menopausal women by reducing estrogen produced by

the body, essentially starving the cancer cells of their fuel supply. The drugs inhibit the production of estrogen, which is synthesized by the enzyme aromatase.

The first aromatase inhibitor was released worldwide in 1994 and had an immediate and lifesaving impact for millions of breast cancer patients, especially since the estrogen hormone serves as a growth factor for nearly 70% of all breast cancers. Compared to other drug therapies, aromatase inhibitors are very well tolerated by most women and significantly reduce the risk of harmful side effects.

Dr. Brodie's work continues to be widely recognized by the scientific and cancer research communities. Select awards include the prestigious Kettering Prize from the General Motors Cancer Research Foundation and the Landon Award from the American Association of Cancer Research. "Dr. Brodie's pioneering research has saved the lives of countless women worldwide," says Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor in Oncology at the University of Maryland School of



Medicine and director of UMGCC. "The development of aromatase inhibitors is arguably one of the most innovative therapeutic advances in treating women with breast cancer in the last quarter century."

Dr. Brodie's quiet demeanor belies her sharp focus in her continued pursuit of finding "a better way." Building on the success of aromatase inhibitors, Brodie and her colleague Vincent Njar, PhD, have developed an androgen inhibitor compound, known as galeterone, to extend their fight against prostate cancer. Today, this compound shows promise in clinical trials as a more effective and well tolerated treatment for the most challenging cases of prostate cancer. Recently, galeterone's approval was fast-tracked by the Food and Drug Administration.

The same characteristics that drew Brodie to the University of Maryland nearly forty years ago "are still present today," states Brodie. "Public and private support are an integral part of our ability to continue our research and attract top talent." Brodie continued, "government funding cuts have made it especially challenging for younger investigators to secure grants at this time, as well as established investigators. Philanthropic partnerships will help us advance."

To learn more and support Dr. Brodie's work, please visit www.ummsfoundation.org/umgcc

2008



UMGCC receives NCI Cancer Center Designation.


For the first time, *U.S. News & World Report* ranks UMGCC as one of the top 50 cancer centers nationwide.

Inaugural Maryland Half Marathon race is co-founded by Michael Greenebaum and Jon Sevel to benefit UMGCC.



2010

UMGCC research team led by Stuart Martin, PhD, discovers that “microtentacles” play a key role in how breast cancers spread to distant locations in the body. His research may help scientists find new ways to prevent metastasis.



Symbol of Hope

Cancer survivor’s winning design is a source of inspiration for the UMGCC community

To cancer patients and their caregivers, a symbol of hope can make all the difference in persevering through tough times. Cancer survivor Sean Maykrantz has now created a very special symbol for patients, faculty, and staff at the University of Maryland Marlene and Stewart Greenebaum Cancer Center: the 61st Annual National Security Agency (NSA) Challenge Coin, which he designed and then presented to UMGCC recipients during a special ceremony. The new coin has already

begun to serve as a beacon for the UMGCC community, beckoning both patients and caregivers toward their goal lines.

The seeds for Sean’s idea were sewn in 2011, while he underwent six months of therapy for Hodgkin’s lymphoma at UMGCC. Even before his diagnosis, the cancer center had become familiar to his father, Larry Maykrantz, President of St. John Properties (SJP). Not only was SJP a lead sponsor of the annual Maryland Half Marathon, founded by Michael Greenebaum for the benefit of UMGCC, but Larry had been working with Michael and his father, Stewart, on a joint venture between their company, Greenebaum Enterprises, and SJP. On the very same day as Sean’s diagnosis, Larry had coincidentally scheduled a business meeting with Stewart Greenebaum.

“Right before the meeting, my wife, Donna, called to say that Sean had been diagnosed with Hodgkin’s lymphoma,” Larry remembers. “Sean was just 25 years old at the time—and he was terrified he would die. As a family, we were devastated by the news and felt lost.”

Larry found the strength to continue on to the critical meeting, where the parties were set to finalize their joint project. Not wishing to burden Stewart with the news of Sean’s diagnosis, Larry kept it inside until the end, briefly asking Stewart for advice about the cancer center. When Larry revealed the reason why, Stewart sprang into action. “Within 15 minutes, Stewart was on the phone with UMGCC,” says Larry. “Sean’s first appointment was the following Monday, and Stewart came by to check in. Our family will forever appreciate the comfort and support he offered during that extremely dark period.”

Though Sean knew he was in the best of hands, with a cutting-edge treatment regimen led by UMGCC lymphoma expert Aaron Rapoport, MD, the experience was especially grueling due to his new job as a graphic designer at the Department of Defense—which he continued to hold down during his entire course of treatment. In addition to his regular responsibilities, Sean had been asked to participate in a special competition to design the 61st Challenge Coin



The Maykrantz family at the 2014 UMGCC Golf Tournament. From left to right: Adrienne Lundy, Sean’s fiancée, Sean, Donna, and Larry Maykrantz.

for the NSA. Given by units throughout the military, Challenge Coins are used to prove membership when challenged and to enhance morale.

Sean’s incredibly hard work paid off in every regard. At the completion of his six-month treatment, he was declared free of cancer, and shortly afterward, he learned he had won the NSA Challenge Coin competition. “We could not have been more proud of all Sean had accomplished,” Larry says, “or more grateful to UMGCC for providing the

state-of-the-art care that saved his life.”


The Maykrantz family has since shown gratitude for the cancer center in multiple ways. Donna and Larry have each become invaluable members of the UMGCC Board of Advisors.

In addition, at a ceremony last October, Sean—who had been in remission for more than three years—bestowed the NSA Challenge Coin to three of its first UMGCC recipients in appreciation for their transformational level of care and support: Stewart

Greenebaum, Dr. Rapoport, and the collective UMGCC team. Larry shared, “the coin is being presented to some very special people in recognition of the tremendous achievements that have been made at UMGCC. This Challenge Coin can serve as a focal point of positive thinking for cancer patients and all those involved in their care. Now, the challenge to you is to continue your fight against cancer, in the hope that one day this disease will be cured!”



2014



Launch of the University of Maryland (UM) Cancer Network establishes formal affiliations between three community cancer centers—**2**UM Baltimore Washington Medical Center’s Tate Cancer Center, **3**UM St. Joseph Medical Center’s Cancer Institute, and **4**UM Upper Chesapeake Health’s Patricia D. and M. Scot Kaufman Cancer Center—with the nationally-recognized UMGCC.

UMGCC establishes a Population Science research program, which is focused on issues of cancer epidemiology, prevention, and disparities and brings together investigators with a range of expertise across multiple UM campuses.

To date, the Maryland Half Marathon & 5K has generated nearly \$2 million in proceeds to benefit research, training and patient care programs at UMGCC.



Serendipity Strikes Close to Home

Author and cancer survivor celebrates strong connections to UMGCC

As a lawyer turned award-winning full-time author, Debbie Levy draws inspiration from many sources. Her bibliography is diverse, ranging from children’s books to texts on medical ethics and civil liberties, and her works are both lighthearted and deeply personal. Several of her projects also reflect Debbie’s passion for storytelling and philanthropy. By what can only be called serendipity, a recent project also strengthened her connection to the University of Maryland Greenebaum Cancer Center.

Long familiar with UMGCC through the work of her husband, Richard Hoffman, on the UMMS Board, and as a former patient herself, Debbie was acutely aware of its outstanding reputation. However, it was a twist of fate that sparked a renewed connection when Debbie’s agent called with a children’s book idea about a marathon-running dog.

Unbeknownst to Debbie, this dog named Dozer had recently received national attention for jumping in with runners of the 2011 Maryland



Half Marathon and completing nearly seven miles of the race course. After she realized this race occurred right here in Maryland and was also a fundraiser for UMGCC, Debbie told her agent, “if someone is going to write that book it should be me!”

Dozer’s Run: A True Story of a Dog and His Race was published in 2014. In addition to the joy she has found

sharing Dozer’s story with readers, Debbie notes another discovery. “Dozer’s appeal is universal. He brought joy to others who were racing to support UMGCC through his cheerful personality. He’s inspired many to give back and continue the fight against cancer.”

Through her work on Dozer’s story, Debbie deepened her own connection with UMGCC. Also a lifelong Marylander, Debbie believes strongly that “we’re fortunate to have an NCI-designated cancer center like UMGCC right here in our backyard so we all can benefit from the discoveries made here.” The people at UMGCC “wear their commitment to research and patient care on their sleeves,” she adds. “I knew I wanted to support these efforts.”

Levy’s philanthropic gift to UMGCC was inspired by her mother, Jutta Salzberg, whose personal story moved her daughter to pen *The Year of Goodbyes: A True Story of Friendship, Family and Farewells*. The book paints a portrait of Jutta’s life as a young girl in 1938 Nazi Germany.

Throughout the book, Jutta’s *poesiealbum*, or autograph book, features prominently and gives the reader a glimpse into everyday life. Prior to Jutta’s death at age 87 in 2013, Levy spent several years alongside her mother, sharing the book with others. “My mother was also a cancer survivor,” Levy notes. “I couldn’t think of a better way to pay tribute to her than to support cancer research. It’s what she would have wanted.”



To learn more about ways to make strides in cancer research, visit www.ummsfoundation.org/umgcc

Children’s Cancer Foundation Grants Wishes for Pediatric Cancer Patients

Through a generous new grant, **The Children’s Cancer Foundation Inc., (CCF)** will expand their partnership with UMGCC and bring the beloved Magic Castle program to the new Maryland Proton Treatment Center upon its completion in 2015. The Magic Castle has long been a joyful symbol of hope for pediatric cancer patients during their course of radiation therapy at UMGCC. Children are invited to write three wishes on a slip of paper and place them inside the castle on the first day of their treatment. On the final day of treatment, the children’s wishes are granted during a special celebration with family members and staff. Thanks to CCF, every pediatric cancer patient will be able to experience the joy of this whimsical diversion. “Our Board of Directors unanimously agreed that the Magic Castle is a truly worthy project,” says Tasha Museles, CCF’s Executive Director.

“It makes us all feel wonderful to give a little piece of magic to these special patients.”

Tasha Museles

Remembering a Remarkable Surgeon and Educator

New endowment commemorates life of cherished faculty member

“Cliff was larger than life,” says UMMS Department of Orthopaedics Chair Andrew Pollak, MD, remembering Clifford Turen, MD—his friend and former colleague who once served as Chief of Orthopaedics at the R Adams Cowley Shock Trauma Center. Dr. Turen tragically passed away in January 2013, when the private plane he was piloting crashed in northern Delaware.

In memory of this extraordinary surgeon, educator, and leader, the University of Maryland has established the Clifford H. Turen, MD Fellowship Endowment Fund. The fund supports the very best young trainees and renowned scholars in the field of Orthopaedic Trauma Surgery.

Dr. Turen came to the Shock Trauma Center as a fellow in 1988. He then spent four years in the Navy as Chief of the Orthopaedic Trauma Service at the Portsmouth Naval Regional Medical Center in Virginia. Dr. Turen returned to Shock Trauma as a part-time consultant and surgeon from 1990 to 1993, becoming a full-time member from 1993 to 2009. During his tenure, Dr. Turen served in various capacities, including Director of the Orthopaedic

Traumatology Fellowship, which contributed to the education of countless fellows and residents who rotated through Shock Trauma, and Program Director of the University’s Orthopaedic Surgery residency program.

“Cliff was an outstanding educator who could both fix the problems others had difficulty with and then teach them how to do it,” remarks Dr. Pollak, also the James Lawrence Kernan Professor in the University of Maryland School of Medicine. The sentiment is shared by Thomas Scalea, MD, Physician-in-Chief at the Shock Trauma Center as well as Director of the Program in Trauma and the Francis X. Kelly Professor of Trauma Surgery in the School of Medicine. Says Dr. Scalea, “Cliff’s effect was international.”

The Turen Fund supports two areas of utmost importance to orthopaedic trauma professionals: fellowships and lectureships. Fellowships offer essential support to junior-level faculty as they establish research careers, gain teaching experience, and provide patient care. The new annual lectureship supported by the fund

will cover travel and expenses for world-renowned orthopaedic trauma scholars to visit the University.

“We are deeply grateful to our generous benefactors for their early leadership gifts to this effort, including George and Chip Doetsch; members of the Boards of Visitors of both the Shock Trauma Center and the Children’s Hospital; Dr. Scalea; the Department of Orthopaedics; and many of Dr. Turen’s trainees, colleagues, and friends,” says Robert O’Toole, MD, Head of the School of Medicine Division of Orthopaedic Trauma and Chief of Orthopaedics at the Shock Trauma Center. “There is no more fitting way to honor Cliff’s legacy than through this enduring fund.”

To learn more, visit

www.ummsfoundation.org/clifford_turen

IMPACT is published by the University of Maryland Medical System Foundation

Jeffrey A. Rivest
President and CEO, UMMC
Janice J. Eisele
Senior Vice President, UMMS Foundation
Copy: Meghan Ray Virro, Stephanie Bruzzese
Design: SDYM, Inc.
Primary Photography: Stephen Spartana

HEALTH MATTERS



UNIVERSITY of MARYLAND
MEDICINE

MEDICAL CENTER AND SCHOOL OF MEDICINE

Thursday, October 22, 2015 | Four Seasons Baltimore | 12:00pm – 2:00pm

Join leading experts from the University of Maryland Medical Center and School of Medicine for a luncheon and panel discussion focused on advancements and discoveries in research and patient care. For more information and registration, please visit www.ummsfoundation.org/HMB